Abstract
For many life-science professionals, biological products represent the cutting edge of medical research and are the smartest means to target and treat a variety of disease and conditions for which the current treatments are still unsatisfactory. In contrast to new chemical entities (NCE), most biologics are complex mixtures that are not easily identified or fully characterized. Nevertheless, due to the rapid development of biotechnology in the last three decades, the number of approved biological drugs is increasing at a faster rate than it is the case for new chemical entities. Biological drugs may be highly specific for a target, are more heat sensitive and susceptible to microbial contamination, and are likely antigenic. Thus, the quality and security testing of biologics is becoming increasingly important. This chapter compares the regulatory environment relevant for biological drugs, with a typical “case-by-case” development program versus NCEs, which are generally developed according to a more standard “classical” manner.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Peer-Reviewed Articles
Baumann A (2009) Nonclinical development of biopharmaceuticals. Drug Discov Today 23–24:1112–1122
Brinks V (2011) Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res 28:2379–2385
Rosenberg AS (2003) Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev Biol (Basel) 112:15–21
Schwieterman WD (2006) Regulating biopharmaceuticals under CDER versus CBER: an insider’s perspective. Drug Discov Today 19–20:945–951
Suntharalingam G (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. New Engl J Med 355(10):1018–1028
Swann PG (2011) Regulatory considerations for development of bioanalytical assays for biotechnology products. Bioanalysis 6:597–603
Regulatory Documents
EMEA/CHMP/BMWP/101695/2006: Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process non-clinical and clinical issues
EMA/CHMP/BWP/534898/2008: Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
EMEA/CHMP/SWP/294648/2007: Guideline on strategies to identify and mitigate risks for first-inhuman clinical trials with investigational medicinal products
EMEA/CHMP/EWP/192217/2009: Guideline on bioanalytical method validation
ICH guidelines: all the guidelines cited in this document are available for download at: http://www.ich.org/products/guidelines.html
Notice to Applicants Volume 2A (2005) Procedures for marketing authorization. Can be downloaded from http://ec.europa.eu/health/documents/eudralex/vol-2/index_en.htm
US Guidance for Industry (2005) “Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers”
US Guidance for Industry (2008) Safety testing of drug metabolites
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Disclaimer:
Any views and opinions expressed in this article are those of the authors and do not necessarily reflect those of any institutions the authors are associated with.
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Ruthsatz, M., Chiavaroli, C., Voisin, E. (2014). Biomolecules Versus Smaller Chemicals in Toxicology. In: Reichl, FX., Schwenk, M. (eds) Regulatory Toxicology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35374-1_57
Download citation
DOI: https://doi.org/10.1007/978-3-642-35374-1_57
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-35373-4
Online ISBN: 978-3-642-35374-1
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences